Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Gastroenterology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
J Gastroenterol Hepatol. 2023 Jul;38(7):1089-1098. doi: 10.1111/jgh.16195. Epub 2023 Apr 29.
Disturbance of gut microbiota is associated with pathological change in multiple diseases. Probiotics can improve symptoms and exert clinical effects via regulation of gastrointestinal microecological environments, and a probiotic product commonly dispensed by Chinese physicians is a combination of live Bifidobacterium, Lactobacillus, and Enterococcus in powder/capsule form. It contains three strains-of Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis-which can act synergistically to balance the microbiome, regulate immunity, and repair the gut barrier. Although this product has been proven safe and effective in clinical practice, uncertainty remains regarding its use to treat digestive system diseases. To date, there have been no reference standards to guide clinical practice and no relevant expert consensus on this product, in China.
Following a literature search, evidence was graded and classified according to the grading of recommendations assessment, development, and evaluation (GRADE) system and consensus was secured from a panel of 52 experts.
An expert consensus has been formed, on the clinical application of live combined Bifidobacterium, Lactobacillus, and Enterococcus in various digestive system diseases, to provide reference for its clinical use.
Bifidobacterium triple viable powder/capsule may offer benefits, by regulating the balance of intestinal microecology. It can be used for the treatment and prevention of various digestive system diseases with good overall safety; further research is needed to confirm its application in other contexts. The recommendations in this consensus will be confirmed or refined in light of future research and clinical practice.
肠道微生物群的紊乱与多种疾病的病理变化有关。益生菌可通过调节胃肠道微生态环境来改善症状并发挥临床疗效，中国医生常用的益生菌产品是一种粉末/胶囊形式的活双歧杆菌、嗜酸乳杆菌和粪肠球菌的组合。它包含三种菌株-长双歧杆菌、嗜酸乳杆菌和粪肠球菌-可以协同作用，平衡微生物组，调节免疫，修复肠道屏障。虽然该产品在临床实践中已被证明是安全有效的，但对于其在消化系统疾病中的应用仍存在不确定性。迄今为止，中国尚无指导临床实践的参考标准，也没有关于该产品的相关专家共识。
通过文献检索，根据推荐评估、制定和评估（GRADE）系统对证据进行分级和分类，并从 52 名专家组成的小组中获得共识。
形成了关于活双歧杆菌、嗜酸乳杆菌和粪肠球菌在各种消化系统疾病中的临床应用的专家共识，为其临床应用提供参考。
双歧杆菌三联活菌粉/胶囊可能通过调节肠道微生态平衡带来益处。它可用于治疗和预防各种消化系统疾病，总体安全性良好；需要进一步的研究来确认其在其他情况下的应用。本共识中的建议将根据未来的研究和临床实践进行确认或完善。
